Roivant Sciences Ltd.
ROIV · Price history
Price at last available close
$37.11
+$0.61 (+1.67%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Roivant Sciences Ltd.
Primary reporting period: 2026-03-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia.
How they make money
Roivant Sciences operates a business model focused on developing transformative medicines and technologies by building agile, focused subsidiary companies known as Vants. The company identifies and acquires promising drug candidates, advances them through clinical development, and seeks regulatory approval and commercialization, often through these specialized entities.
Products & services
Roivant develops a pipeline of pharmaceutical candidates, including brepocitinib for autoimmune and inflammatory diseases, and VTAMA (tapinarof) for dermatological conditions.
Brands & revenue mix
A therapeutic product for dermatological conditions.
Separate brand revenue is not available in this research.Source
A clinical-stage drug candidate for autoimmune and inflammatory diseases.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2026-03-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Business relationships & partnerships
- Moderna — Genevant Sciences (a Roivant subsidiary) and Arbutus entered a settlement agreement with Moderna regarding patent infringement litigation.Source
Competitors
- Pharmaceutical and biotechnology companies — Various companies developing therapies for autoimmune, inflammatory, and dermatological diseases.Source
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
26
Poor
Financial Strength
20
Business Quality / Moat
33
Management
40
Growth Quality
14
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
23
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
33/100
Building Historical Record
Model Score 33/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for ROIV
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving ROIV's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can ROIV fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ROIV likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ROIV to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ROIV's current valuation?
Essential Investment Snapshot
Wall Street Score
22
Opportunity Score
23
Market Cap
$26.81B
P/E Ratio
-89.6
EPS
$-0.38
52-Week High
$42.50
52-Week Low
$17.28
Beta
1.10
Analyst Target
$47.00
Shares Outstanding
693.9M
Total Revenue
$7.5M
Total Debt
$107.2M
Dividend
No current dividend
Liquidation Value / Share
$7.09
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ROIV
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on ROIV.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong cash position and liquidity.
- +Agile Vant-based development model.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Clinical trial failure and regulatory approval risks.
- −Dependence on successful commercialization of pipeline assets.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
22
Oct 15, 2026
Change
+0.1
points
Current Score
22
Oct 19, 2026
Category Changes
ROIV increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
18
Projected Change
-4.2 points
Preliminary comparable-period financial changes suggest decline of approximately 4.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$37.11
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -71.6%
Revenue changed sharply from 2025 to 2026. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $8.3M | $29.1M | $32.7M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.4M | $1.3M | $911K | $1.6M | ···· | ···· | ···· | ···· |
| Gross Profit | $6.1M | $7.0M | $28.1M | $31.1M | ···· | ···· | ···· | ···· |
| Research & Development | $730.9M | $681.8M | $550.4M | $439.9M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $642.0M | $610.5M | $591.4M | $416.1M | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.37B | $1.29B | $1.14B | $856.0M | ···· | ···· | ···· | ···· |
| EBITDA | -$287.0M | -$261.2M | -$667.5M | $4.62B | ···· | ···· | ···· | ···· |
| Operating Income | -$1.37B | -$1.29B | -$1.11B | -$824.9M | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $34.8M | ···· | ···· | ···· | ···· |
| Income Before Tax | -$289.9M | -$264.6M | -$681.6M | $4.57B | ···· | ···· | ···· | ···· |
| Income Tax Expense | $124.7M | $133.3M | $48.2M | $21.5M | ···· | ···· | ···· | ···· |
| Net Income | -$266.2M | -$299.8M | -$172.0M | $4.35B | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.36 | $-0.43 | $-0.24 | $5.55 | ···· | ···· | ···· | ···· |
| Basic Shares | 721M | 694M | 725M | 783M | ···· | ···· | ···· | ···· |
| Diluted Shares | 721M | 694M | 725M | 831M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.4M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.26
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+7.5%
Cash Change
+0.8%
Margin Change
-2871.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included revenue growth, EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 33.5%. EPS declined 21.2%. Cash increased 0.8%. Total debt increased 7.5%. Net income margin declined by 2871.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
Roivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)
Rumor Mill · ROIV
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial